These outcomes are drawn from deployed pilot cohorts across multiple organization types. Every figure is aggregate and de-identified. Where validation is still in progress — specifically VLAP signal accuracy — that is stated clearly. We don't claim more than the data supports.
All figures below are from deployed pilot cohorts. Figures without a validation note are from aggregate program data. VLAP signal accuracy figures are from active IRB research with the University of Maryland — results are preliminary and pending peer-reviewed publication.
A direct comparison against traditional care pathways and generic digital behavioral health platforms — for the specific populations Vasl serves. Industry figures are drawn from published literature; sources available on request.
Sources available on request · Vasl figures from pilot cohort aggregate data
PHQ-8 improvement isn't a single measurement — it's a trajectory. These data points show how symptom reduction develops across a 90-day deployment period in pilot cohorts. The 42% headline figure is the 90-day outcome; the intermediate figures show the arc of change.
Member enrolls, receives coach outreach within 48 hours, joins peer community. Baseline PHQ-8 and GAD-7 completed during onboarding. No clinical change expected at this stage — the focus is access and connection.
Consistent coaching relationship established. Peer community engagement active. First measurable mood trend data available in VLAP. Early PHQ-8 changes visible but not yet statistically significant at cohort level.
Members who remain engaged at week 8 show meaningful symptom reduction. Clinical coordination has begun for the ~20% who benefit from licensed clinical support. 79.5% retention rate sustained at this checkpoint.
The 90-day measurement point. 79.5% of enrolled members still active. Average PHQ-8 improvement reaches 42% across the retained cohort — the figure reported in all Vasl outcome documentation.
Vasl's clinical outcomes come from deployed pilot programs — real members, real organizations, real data. The VLAP validation research adds a layer of independent academic rigor through an active IRB-approved study. Here's the methodology behind both.
An IRB-approved study is in progress with the University of Maryland validating CulturalBERT-VLAP's signal detection accuracy against clinician-adjudicated ground truth assessments. The study uses production deployment data from live Vasl cohorts. Results will be published in a peer-reviewed journal upon completion. This is the primary independent validation of VLAP's culturally specific signal detection claims.
Outcome measurement uses gold-standard validated instruments: the PHQ-8 (Patient Health Questionnaire, 8 items) for depression symptom measurement, administered at onboarding and at 90 days. The GAD-7 (Generalized Anxiety Disorder, 7 items) for anxiety symptom measurement, using the same protocol. Both instruments have extensive validation literature. The cultural limitations of these instruments — validated predominantly on majority-White populations — are noted in clinical documentation and addressed through VLAP's complementary signal detection.
Program-level outcome data is drawn from aggregate, de-identified records across pilot deployments — not from a randomized controlled trial. The pilot cohort data reflects real-world deployment conditions: members who enrolled and engaged with the platform over 90 days. The 79.5% retention figure and 42% PHQ-8 improvement reflect the engaged cohort. We do not report outcomes for members who disengaged before 90 days as evidence of program failure — we report them as attrition. The distinction matters for interpreting the data accurately.
Pilot cohorts include BIPOC, LGBTQ+, and first-generation youth populations — the specific communities Vasl's platform was built to serve. Outcomes are measured across these population groups, and demographic disaggregation of outcomes is available to institutional partners under data sharing agreements. The cohort composition is what makes the 79.5% retention and 42% PHQ-8 improvement figures meaningful: these outcomes were achieved in the populations for whom standard care consistently underperforms.
The outcomes brief includes detailed methodology, statistical analysis, cohort demographics, disaggregated outcomes by population subgroup, and implementation context. Available to qualified institutional evaluators under NDA.